A study of beta-cell function after glucagon stimulation in thalassaemia major treated by high transfusion programme.
An increased incidence of diabetes mellitus and glucose intolerance has been reported in thalassaemia major treated with a high transfusion programme (HTP). To investigate beta-cell function, serum immunoreactive insulin (IRI), C-peptide (CP) and glucose were measured fasting and at 3, 6 and 10 min after i.v. administration of 1 mg glucagon in 20 thalassaemia patients treated by many transfusions and in nine healthy control subjects. Fasting C-peptide concentrations (mean +/- SEM) were higher in the thalassaemic group (2.15 +/- 0.17 ng/ml) than in the controls (1.41 +/- 0.13 ng/ml). After stimulation with glucagon, C-peptide concentrations were consistently higher (P less than 0.01) by approximately 50% in the thalassaemic than in the control group (5.29 +/- 0.31 vs 3.36 +/- 0.21 ng/ml, at 3 min; 5.22 +/- 0.30 vs 3.53 +/- 0.21 ng/ml at 6 min and 4.69 +/- 0.27 vs 3.30 +/- 0.17 ng/ml after 10 min). Plasma IRI concentrations increased in both groups after glucagon stimulation but were not significantly different. The glucose values were approximately 15% higher at each sampling time in the thalassaemic group than those of the normal subjects. It is concluded that disturbances in carbohydrate metabolism in thalassaemia major treated with HTP are the consequence of hepatic cirrhosis which accompanies secondary haemosiderosis, and possibly iron deposition in the beta-cells of the pancreas.
Livadas
D P
DP
Venizelion General Hospital, Endocrinologic Unit, Heraklion-Crete, Greece.
Economou
E
E
Sofroniadou
K
K
Fotiadou-Pappa
H
H
Van Melle
G D
GD
Temler
E
E
Felber
J P
JP
D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001803:Blood Transfusion; D002096:C-Peptide / Q000097:blood; D005260:Female; D005934:Glucagon; D006801:Humans; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000503:physiopathology*; D008297:Male; D013789:Thalassemia / Q000097:blood / Q000503:physiopathology* / Q000628:therapy
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D005934:Glucagon